Qingdao Vland Biotech INC. News

Blue Biotech (603739): Enzyme formulation sector continues to grow, multiple business layouts work together

Sep 9, 2024 07:36

Blue Biotech (603739): Technology-driven development capacity layout is basically completed

Sep 8, 2024 00:00

Weilan Biotech (603739) 23 Annual Report and '24 Quarterly Report Review: R&D Drives Market to Support Peak Performance of Enzyme Formulations

May 9, 2024 00:00

Blue Biotech (603739): Steady growth in revenue and net profit driven by R&D to raise gross margin level

May 7, 2024 07:31

Blue Bio (603739): 24Q1 enzyme preparation has impressive growth rate and multiple ways to create a big animal health system

Apr 30, 2024 15:36

Blue Biology (603739): Performance growth is in line with expectations and continues to improve the animal health system

Apr 30, 2024 07:21

Blue Biotech (603739): R&D drives steady development of Maori microecology industry

Apr 30, 2024 00:00

Blue Biotech (603739) In-depth Report: In line with major health trends, optimistic about the long-term business development of enzyme preparations and probiotics

Feb 7, 2024 13:21

Weilan Biotech (603739) Three Quarterly Report Review: High R&D Drives Rapid Growth in High Maori Enzyme Formulation Business

Nov 3, 2023 00:00

Blue Biotech (603739): R&D drives Maori profit growth, production capacity climbs, and can be expected in the future

Southwest SecuritiesOct 29, 2023 00:00

Blue Biotech (603739): Enzyme products lead performance growth, significant results in cost reduction and efficiency

CSCOct 28, 2023 09:32

Blue Biology (603739): 2023H1 revenue is growing steadily, and businesses such as enzyme preparations, animal protection, and microecology are developing comprehensively

國信證券Sep 5, 2023 20:46

Azure Biology (603739): More flowering increases production capacity

中泰證券Aug 27, 2023 00:00

Blue Biotech (603739): 23Q2 main business grew significantly, solid capital expansion led to performance improvement

中信建投證券Aug 24, 2023 00:00

Blue Biotech (603739): Acquisition of Runbo's Supplement Compulsory Drug Business Continues to Improve Animal Health Systems

中信建投證券Jul 21, 2023 12:42

Weilan Biotech (603739): Health insurance related businesses are under pressure in 2023Q1, and new business layouts such as probiotics are progressing steadily

國信證券Apr 30, 2023 00:00

Blue Biology (603739): Probiotic research and development goes further, prospects for development in many sectors are bright

西南證券Mar 24, 2023 20:12

Blue Bio (603739): The accelerated process of the food probiotic project can be expected

中泰證券Mar 23, 2023 00:00

Blue Bio (603739): The rise in enzyme preparation boom increases the new engine of probiotics

中泰證券Mar 10, 2023 00:00

Weilan Biotech (603739): Revenue improved month-on-month in the third quarter, and profitability was under slight pressure

中信建投證券Oct 30, 2022 00:00